In a distinct subgroup of NSCLC, comprising approximately 1%–3%, HER2 mutations are recognized as genomic drivers, yet no HER2-targeted treatment has gained official approval for NSCLC. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.